Edition:
India

Arena Pharmaceuticals Inc (ARNA.OQ)

ARNA.OQ on NASDAQ Stock Exchange Global Select Market

64.43USD
1:30am IST
Change (% chg)

$0.82 (+1.29%)
Prev Close
$63.61
Open
$64.30
Day's High
$64.47
Day's Low
$63.38
Volume
112,027
Avg. Vol
266,475
52-wk High
$69.69
52-wk Low
$33.00

Latest Key Developments (Source: Significant Developments)

Arena Pharmaceuticals Q2 Loss Per Share $1.24
Thursday, 8 Aug 2019 

Aug 7 (Reuters) - Arena Pharmaceuticals Inc ::ARENA REPORTS SECOND QUARTER FINANCIAL RESULTS WITH STRONG LIQUIDITY POSITION, AND INITIATION OF ETRASIMOD ELEVATE UC 52 AND OLORINAB CAPTIVATE TRIALS.Q2 LOSS PER SHARE $1.24.Q2 REVENUE $1.0 MILLION.Q2 REVENUE ESTIMATE $2.9 MILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE ESTIMATE $-1.08 -- REFINITIV IBES DATA.  Full Article

Arena Pharmaceuticals Says Had About $528 Mln Of Cash, Cash Equivalents And Investments As Of Dec 31
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Arena Pharmaceuticals Inc ::ARENA PHARMACEUTICALS INC - AS OF DECEMBER 31, 2018, HAD ABOUT $528 MILLION OF CASH, CASH EQUIVALENTS, AND INVESTMENTS.  Full Article

Arena Pharmaceuticals Reports Positive Long-Term Data From The Open-Label Extension Of The Phase 2 Oasis Trial
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Arena Pharmaceuticals Inc ::ARENA PHARMACEUTICALS REPORTS POSITIVE LONG-TERM DATA FROM THE OPEN-LABEL EXTENSION OF THE PHASE 2 OASIS TRIAL EVALUATING ETRASIMOD FOR TREATMENT OF ULCERATIVE COLITIS.ARENA PHARMACEUTICALS INC - ETRASIMOD DEMONSTRATED CLINICAL RESPONSE AND DURABLE, LONG-TERM CLINICAL REMISSION.ARENA PHARMACEUTICALS INC - ETRASIMOD DEMONSTRATED FAVORABLE LONG-TERM SAFETY AND TOLERABILITY.  Full Article

Arena Pharma Reports Positive Phase 2A Results For Olorinab
Tuesday, 25 Sep 2018 

Sept 24 (Reuters) - Arena Pharmaceuticals Inc ::ARENA PHARMACEUTICALS REPORTS POSITIVE PHASE 2A RESULTS FOR OLORINAB IN PATIENTS WITH ABDOMINAL PAIN ASSOCIATED WITH CROHN'S DISEASE.ARENA PHARMACEUTICALS INC - OLORINAB APPEARED SAFE AND GENERALLY WELL TOLERATED.ARENA PHARMACEUTICALS INC - ARENA INTENDS TO PROGRESS OLORINAB CLINICAL PROGRAM TARGETING GASTROINTESTINAL PAIN.ARENA PHARMACEUTICALS INC - OLORINAB DEMONSTRATED A STATISTICALLY SIGNIFICANT IMPROVEMENT IN ABDOMINAL PAIN OVER 8 WEEKS OF TREATMENT.ARENA PHARMACEUTICALS INC - TREATMENT EFFECTS WERE DEMONSTRATED EARLY AND WERE CONSISTENT OVER 8-WEEK TREATMENT PERIOD.ARENA PHARMACEUTICALS INC - ALL PATIENTS WITH EVALUABLE DATA AT WEEK 8 EXHIBITED A PRE-DEFINED CLINICAL RESPONSE OF ≥30% CHANGE FROM BASELINE IN AAPS.  Full Article

BRIEF-Arena Pharmaceuticals Says Board Increased Size Of Board To 9 Directors - SEC Filing

* ARENA PHARMACEUTICALS SAYS BOARD INCREASED SIZE OF BOARD FROM 8 DIRECTORS TO 9 DIRECTORS - SEC FILING Source text: https://bit.ly/2Yc3Trb Further company coverage: